RyR1 Structural Alterations Explain Statin-Associated Muscle Dysfunction
December 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Background
Ketosis-prone diabetes (KPD) exists as a syndrome which causes diabetic ketoacidosis (DKA) among people who do not show characteristics of typical type 1 or type 2 diabetes diagnosis. The medical community discovered KPD in the 1960s when studying diabetes in African and African American patients which combines characteristics from both diabetes types. The proper management in KPD patients can trigger spontaneous remission that leads to insulin independence together with better insulin sensitivity. Type 1b diabetes and LADA represent the names assigned to KPD which presents DKA symptoms but does not require continuing insulin treatment. According to the Aβ classification system patients receive assessments of their beta-cell reserve combined with their autoantibody status to divide them into four distinct categories. Type 2-like traits require oral medications but patients with permanent insulin dependence need lifelong treatment.
Epidemiology
Ketosis-prone diabetes (KPD) affects between 20% to 50% of African American and Hispanic patients who experience diabetic ketoacidosis (DKA) with half of them displaying the A-β+ phenotype in the United States. The frequency of DKA for the population in African countries matches identically with North American populations yet the Asian and White population demographics manifest lower frequencies of DKA at below 10%. The occurrence of KPD appears twice to three times higher in male patients than female patients. The evaluation of KPD normally happens between the ages of thirty and fifty but healthcare providers have spotted this condition in children as well.
Anatomy
Pathophysiology
The factors that cause diabetic ketoacidosis (DKA) to occur in the A-β+ subgroup of ketosis-prone diabetes (KPD) remain unclear although viral infections, G6PD deficiency-induced oxidative stress and genetics are suspected contributors. Acute hyperglycemia produces substantial impairment of C-peptide response in affected patients according to research findings but chronic hyperglycemia weakens insulin signaling in skeletal muscle resulting in reversible β-cell dysfunction. The detection of B-chain amino acid 9-23-related peptide through immunoreactivity indicates reduced β-cell performance in patients with A-β+ and DKA.
Etiology
Relevant research continues to investigate the origins of multiple diabetic disorders. The severity of the condition and extent of β-cell destruction align with different epitopes present in glutamic acid decarboxylase antibodies. A-β+ phenotype exists due to three major causes which include viral infections together with genetic factors and oxidative stress. Patients who develop ketosis-prone type 2 diabetes have obesity as well as inherited diabetic conditions in their family history.
Genetics
Prognostic Factors
The male population bears a higher risk of this condition by a ratio of two to three since hormonal differences combine with body fat distributions and insulin sensitivity levels. The prognosis of ketosis-prone diabetes depends heavily on whether the patient exhibits the Aβ status. People assigned to the β- category maintain their blood sugar control by using insulin treatments which will last for their entire lives. The majority of A-β+ subgroup patients who suffer diabetic ketoacidosis during their first episode subsequently experience treatment-induced sustained remission that leads to insulin-free remission status.
Clinical History
Age Group:
Typically diagnosed in adults, but cases can occur in children.
Physical Examination
Altered mental status
Tachycardia
Tachypnea/hyperpnea
Hypotension
Nausea, vomiting
Dry mucous membranes
Poor skin turgor
Signs related to a precipitating illness
Age group
Associated comorbidity
“Unprovoked” KPD often lacks precipitating factors, while “provoked” KPD may be linked to acute illnesses (e.g., myocardial infarction, infections).
Patients with long-standing diabetes may show high frequencies of HLA class II susceptibility alleles and T-cell reactivity to islet autoantigens.
Associated activity
Acuity of presentation
Unprovoked KPD: Presents with diabetic ketoacidosis (DKA) without clear triggers. Symptoms include polydipsia, polyuria, and fatigue, with potential for long-term remission and insulin independence.
Provoked KPD: Characterized by a more progressive symptom onset, often associated with acute events. Symptoms may include abdominal pain, which is common, especially in children, and may relate to the severity of acidosis. Shortness of breath despite normal oxygen saturation can also occur.
Differential Diagnoses
Type 1 Diabetes Mellitus (T1DM)
Type 2 Diabetes Mellitus (T2DM)
Latent Autoimmune Diabetes in Adults (LADA)
Maturity-Onset Diabetes of the Young (MODY)
Secondary Diabetes
Infections
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Acute Management:
The patient requires an intravenous administration of fluids to restore both hydration levels and electrolyte balance.
Insulin Therapy: IV insulin infusion for hyperglycemia and ketosis resolution.
Medical staff will monitor both potassium phosphate and bicarbonate levels along with essential replacements when needed.
Transition to Maintenance:
The vast majority of patients initially need treatment with basal-bolus insulin therapy after being admitted to the hospital.
Some patients require the replacement of original oral hypoglycemic agents with either metformin, SGLT2 inhibitors or GLP-1 receptor agonists.
Long-term Management:
Insulin-dependent individuals have the potential for insulin discontinuation after transferring to management with oral anti-diabetic medications.
The three vital elements for success include modifications to diet and exercise along with managing weight.
Regular Performances of Glucose Testing and Assessment of Ketones Help Identify Relapse.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-a-non-pharmacological-approach-for-treating-ketosis-prone-type-2-diabetes
The dietary management approach includes a balanced diet of whole foods that requires controlled carbohydrate intake to maintain steady blood glucose levels.
Physical activity plays a vital role in maintaining health so recommend at least 150 minutes of aerobic and resistance training performed each week. A healthy weight management plan combining proper nutrition with physical activity helps patients achieve better insulin sensitivity. Reducing blood glucose stress effects through implementation of mindfulness practices with relaxation techniques and sleep hygiene practices. The healthcare provider should deliver diabetes education and teach blood glucose monitoring to patients while training them to detect symptoms of ketosis.
Role of Antidiabetics, Insulins
Regular Insulin (Humulin R, Novolin R): Onset in 0.5 hours, peak at 2-4 hours, and duration of 5-8 hours. Available in mixtures with NPH insulin.
Insulin Detemir (Levemir): Long-acting, administered once or twice daily, with a duration of 5.7 to 23.2 hours depending on the dose. It regulates glucose metabolism.
Insulin Glargine (Lantus): Long-acting with a consistent release over 24 hours and no pronounced peaks, but potential cancer risk associated.
Role of Antidiabetics, biguanides
Metformin: The diabetes medicine Metformin operates as a solo medication and functions with sulfonylureas and thiazolidinediones and insulin. The patient can minimize gastrointestinal side effects by taking Metformin with food. The drug exists on the market as extended-release forms and also combined with various diabetes treatments. The drug has strict contraindications for patients who have reduced renal function when their serum creatinine reaches levels higher than 1.5 mg/dL in males or 1.4 mg/dL in females or when estimated GFR goes below 60 mL/min. Additionally, metformin should not be used for 48 hours following IV iodinated contrast media treatments.
Role of Antidiabetics, Amylinomimetics
Pramlintide Acetate: It represents a synthetic version of human amylin hormone which pancreatic beta cells produce and type 1 diabetes patients are lacking. The medication achieves these effects by delaying stomach emptying along with its capability to decrease post-meal glucagon release and through its appetite control mechanisms in the central nervous system.
Role of Antidiabetics, Sulfonylureas
Glyburide: Patients receive Glyburide through three trade names including Micronase DiaBeta and Glynase since this second-generation sulfonylurea provides stronger potency while minimizing drug interactions found in first-generation sulfonylureas. Glyburide stands as an alternative treatment option to insulin for managing gestational diabetes even though it lacks specific FDA approval for this medical application.
Glipizide: The second-generation sulfonylurea Glipizide delivers enhanced potency together with reduced drug interactions between this and other first-generation agents. The medication assists natural insulin secretion and produces lesser adverse effects on blood sugar control and body weight than alternative sulfonylurea drugs.
Role of Hypoglycemia Antidotes
Glucagon: Its function is to elevate blood glucose through blocking glycogen synthesis and supporting gluconeogenesis production primarily from protein and fat-based substances. Through liver hepatic glycogenolysis the breakdown of glycogen into glucose stimulates both lipolysis of adipose tissue and glycogenolysis of liver tissues. Glucagon enhances heart muscle contractions and causes relaxed state of gastrointestinal tract functions.
Role of Antidiabetics, Meglitinide Derivatives
Repaglinide: It functions well in patients with high hypoglycemia risks whose treatment needs an insulin secretagogue. Pancreatic beta cells release insulin due to this medication while postprandial blood sugar remains in control. The FDA has approved the drug for individual usage as well as pairing it with metformin or thiazolidinediones.
Nateglinide (Starlix): Â It uses mechanisms that duplicate native insulin activity by releasing insulin early in the day while controlling blood glucose spike amounts during meals. Pharmacological studies have established nateglinide as a suitable option for monotherapy treatment of type 2 diabetes or its use with metformin and thiazolidinediones therapies. Both 60 mg and 120 mg Nateglinide are available as tablets in their dosage form.
Role of Antidiabetics, Alpha-Glucosidase Inhibitors
Miglitol (Glyset): It functions as an unadsorbed FDA-approved pharmaceutical agent that works independently or with sulfonylureas while preserving liver health. These drug characteristics demonstrate both minimal blood sugar reduction together with substantial side effects that cause gas production.
Acarbose (Precose): It provides the first FDA-approved alpha-glucosidase inhibitor treatment because it requires minimal absorption yet it sometimes leads to uncommon liver function problems. Acarbose has two use options as either a single treatment or with other treatment plans.
Role of Antidiabetics, Thiazolidinediones
Pioglitazone (Actos): It is administered to patients alongside dietary modifications and exercise for better type 2 diabetes management through enhanced insulin sensitivity without affecting pancreatic insulin production. Triglyceride levels decrease effectively when patients take this medication due to its PPAR-alpha effect. Professional advice from the FDA states that patients with current bladder cancer must avoid this treatment while healthcare providers need to carefully consider prescribing Actos to those who have battled bladder cancer during the past.
Rosiglitazone (Avandia): It functions as an insulin sensitizer which controls plasma insulin levels by improving glucose uptake in muscle and fat tissues. This medication serves people with type 2 diabetes yet it works best when combined with other therapeutic treatments. The medication helps maintain beta-cell functionality while providing health benefits for blood vessels.
Role of Antidiabetics, Glucagonlike Peptide-1 Agonists
Exenatide Injectable Solution (Byetta): It functions through GLP-1 agonism to help patients with type 2 diabetes control their blood sugar by triggering insulin release in response to glucose while reducing excessive glucagon output and reducing gastric emptying speed. The medicine requires two subcutaneous administrations each day to patients who show inadequate blood sugar management with metformin or sulfonylureas.
Exenatide Injectable Suspension (Bydureon): It enables once-weekly subcutaneous delivery that leads to better glycemic control than Byetta’s twice-daily administration.
Liraglutide (Victoza): It functions as a once-daily GLP-1 receptor agonist that activates pancreatic beta cells to release insulin following blood glucose elevation. Type 2 diabetic adults can take this medication together with diet and exercise yet it functions as secondary treatment only because it carries potentially dangerous adverse effects. The medication must be avoided for patients who have medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 given potential thyroid tumor development concerns.
Role of Antidiabetics, Dipeptidyl Peptidase IV Inhibitors
Sitagliptin (Januvia): It functions as a specific DPP-4 inhibitor which operates without touching either DPP-8 or DPP-9 activity. This drug functions effectively independently or with metformin or thiazolidinediones and patients need to take it once per day. Sitagliptin is weight neutral.
Saxagliptin (Onglyza): It works by blocking DPP-4 activity to enhance the levels of GIP and GLP-1 and subsequently stimulates insulin release for maintaining blood glucose control after meals. The medication functions together with adequate dietary plan and exercise for type 2 diabetes patients aged 18 years and older.
Linagliptin (Tradjenta): It blocks DPP-4 enzyme activity to expand incretin hormone duration thus allowing patients with type 2 diabetes to lower their blood glucose levels. Doctors can prescribe linagliptin either alone or combined with the drugs metformin and sulfonylureas and pioglitazone yet it should not be used with insulin treatment.
Role of Bile Acid Sequestrants
Colesevelam (WelChol): It provides glycemic control benefits for type 2 diabetes mellitus patients through its combination with diet and exercise. Experts have not determined all aspects of the method by which this medication improves blood sugar control.
Role of Antidiabetics, Intermediate-Acting Insulins
Insulin NPH: It shows three to four hours of onset with peak effects during eight to fourteen hours which result in sixteen to twenty-four hours of duration of action. Patients should mix the insulin carefully because its cloudy appearance and ensures discarding the medicine when clumps develop.
Role of Antiparkinson Agents, Dopamine Agonists
Bromocriptine (Cycloset): It represents the single bromocriptine medicine available for type 2 diabetes mellitus treatment through quick-release formulation. Bromocriptine serves as a supplemental treatment with diet and workout to improve blood sugar control.
use-of-intervention-with-a-procedure-in-treating-ketosis-prone-type-2-diabetes
The emergency administration of intravenous insulin represents an essential treatment in DKA situations to manage blood glucose levels and stop ketone production.
A subcutaneous insulin therapy such as basal-bolus insulin therapy becomes the starting point for glycemic regulation after patients have stabilized. Normal saline administration through the intravenous route restores both intravascular volume and corrects dehydration problems from DKA.
The assessment of potassium along with other electrolyte levels remains vital due to insulin treatment which causes potassium to reenter cells thereby inducing hypokalemia.
use-of-phases-in-managing-ketosis-prone-type-2-diabetes
The treatment of ketosis-prone type 2 diabetes requires a step-by-step process which consists of three distinct phases.
The acute phase demands rapid intervention through IV insulin delivery combined with fluid administration to stabilize the patient along with electrolyte control and DKA correction.
During the transition phase patients need to start subcutaneous insulin while receiving education about blood glucose testing and ketone monitoring and learning dietary techniques that stop ketosis from happening.
Regular medical check-ups involve both lifestyle adaptation and the monitoring of glucose levels which helps patients sustain good blood sugar control and avoid further diabetes occurrences.
Medication
Future Trends
Ketosis-prone diabetes (KPD) exists as a syndrome which causes diabetic ketoacidosis (DKA) among people who do not show characteristics of typical type 1 or type 2 diabetes diagnosis. The medical community discovered KPD in the 1960s when studying diabetes in African and African American patients which combines characteristics from both diabetes types. The proper management in KPD patients can trigger spontaneous remission that leads to insulin independence together with better insulin sensitivity. Type 1b diabetes and LADA represent the names assigned to KPD which presents DKA symptoms but does not require continuing insulin treatment. According to the Aβ classification system patients receive assessments of their beta-cell reserve combined with their autoantibody status to divide them into four distinct categories. Type 2-like traits require oral medications but patients with permanent insulin dependence need lifelong treatment.
Ketosis-prone diabetes (KPD) affects between 20% to 50% of African American and Hispanic patients who experience diabetic ketoacidosis (DKA) with half of them displaying the A-β+ phenotype in the United States. The frequency of DKA for the population in African countries matches identically with North American populations yet the Asian and White population demographics manifest lower frequencies of DKA at below 10%. The occurrence of KPD appears twice to three times higher in male patients than female patients. The evaluation of KPD normally happens between the ages of thirty and fifty but healthcare providers have spotted this condition in children as well.
The factors that cause diabetic ketoacidosis (DKA) to occur in the A-β+ subgroup of ketosis-prone diabetes (KPD) remain unclear although viral infections, G6PD deficiency-induced oxidative stress and genetics are suspected contributors. Acute hyperglycemia produces substantial impairment of C-peptide response in affected patients according to research findings but chronic hyperglycemia weakens insulin signaling in skeletal muscle resulting in reversible β-cell dysfunction. The detection of B-chain amino acid 9-23-related peptide through immunoreactivity indicates reduced β-cell performance in patients with A-β+ and DKA.
Relevant research continues to investigate the origins of multiple diabetic disorders. The severity of the condition and extent of β-cell destruction align with different epitopes present in glutamic acid decarboxylase antibodies. A-β+ phenotype exists due to three major causes which include viral infections together with genetic factors and oxidative stress. Patients who develop ketosis-prone type 2 diabetes have obesity as well as inherited diabetic conditions in their family history.
The male population bears a higher risk of this condition by a ratio of two to three since hormonal differences combine with body fat distributions and insulin sensitivity levels. The prognosis of ketosis-prone diabetes depends heavily on whether the patient exhibits the Aβ status. People assigned to the β- category maintain their blood sugar control by using insulin treatments which will last for their entire lives. The majority of A-β+ subgroup patients who suffer diabetic ketoacidosis during their first episode subsequently experience treatment-induced sustained remission that leads to insulin-free remission status.
Age Group:
Typically diagnosed in adults, but cases can occur in children.
Altered mental status
Tachycardia
Tachypnea/hyperpnea
Hypotension
Nausea, vomiting
Dry mucous membranes
Poor skin turgor
Signs related to a precipitating illness
“Unprovoked” KPD often lacks precipitating factors, while “provoked” KPD may be linked to acute illnesses (e.g., myocardial infarction, infections).
Patients with long-standing diabetes may show high frequencies of HLA class II susceptibility alleles and T-cell reactivity to islet autoantigens.
Unprovoked KPD: Presents with diabetic ketoacidosis (DKA) without clear triggers. Symptoms include polydipsia, polyuria, and fatigue, with potential for long-term remission and insulin independence.
Provoked KPD: Characterized by a more progressive symptom onset, often associated with acute events. Symptoms may include abdominal pain, which is common, especially in children, and may relate to the severity of acidosis. Shortness of breath despite normal oxygen saturation can also occur.
Type 1 Diabetes Mellitus (T1DM)
Type 2 Diabetes Mellitus (T2DM)
Latent Autoimmune Diabetes in Adults (LADA)
Maturity-Onset Diabetes of the Young (MODY)
Secondary Diabetes
Infections
Acute Management:
The patient requires an intravenous administration of fluids to restore both hydration levels and electrolyte balance.
Insulin Therapy: IV insulin infusion for hyperglycemia and ketosis resolution.
Medical staff will monitor both potassium phosphate and bicarbonate levels along with essential replacements when needed.
Transition to Maintenance:
The vast majority of patients initially need treatment with basal-bolus insulin therapy after being admitted to the hospital.
Some patients require the replacement of original oral hypoglycemic agents with either metformin, SGLT2 inhibitors or GLP-1 receptor agonists.
Long-term Management:
Insulin-dependent individuals have the potential for insulin discontinuation after transferring to management with oral anti-diabetic medications.
The three vital elements for success include modifications to diet and exercise along with managing weight.
Regular Performances of Glucose Testing and Assessment of Ketones Help Identify Relapse.
Endocrinology, Reproductive/Infertility
The dietary management approach includes a balanced diet of whole foods that requires controlled carbohydrate intake to maintain steady blood glucose levels.
Physical activity plays a vital role in maintaining health so recommend at least 150 minutes of aerobic and resistance training performed each week. A healthy weight management plan combining proper nutrition with physical activity helps patients achieve better insulin sensitivity. Reducing blood glucose stress effects through implementation of mindfulness practices with relaxation techniques and sleep hygiene practices. The healthcare provider should deliver diabetes education and teach blood glucose monitoring to patients while training them to detect symptoms of ketosis.
Endocrinology, Reproductive/Infertility
Regular Insulin (Humulin R, Novolin R): Onset in 0.5 hours, peak at 2-4 hours, and duration of 5-8 hours. Available in mixtures with NPH insulin.
Insulin Detemir (Levemir): Long-acting, administered once or twice daily, with a duration of 5.7 to 23.2 hours depending on the dose. It regulates glucose metabolism.
Insulin Glargine (Lantus): Long-acting with a consistent release over 24 hours and no pronounced peaks, but potential cancer risk associated.
Metformin: The diabetes medicine Metformin operates as a solo medication and functions with sulfonylureas and thiazolidinediones and insulin. The patient can minimize gastrointestinal side effects by taking Metformin with food. The drug exists on the market as extended-release forms and also combined with various diabetes treatments. The drug has strict contraindications for patients who have reduced renal function when their serum creatinine reaches levels higher than 1.5 mg/dL in males or 1.4 mg/dL in females or when estimated GFR goes below 60 mL/min. Additionally, metformin should not be used for 48 hours following IV iodinated contrast media treatments.
Endocrinology, Reproductive/Infertility
Pramlintide Acetate: It represents a synthetic version of human amylin hormone which pancreatic beta cells produce and type 1 diabetes patients are lacking. The medication achieves these effects by delaying stomach emptying along with its capability to decrease post-meal glucagon release and through its appetite control mechanisms in the central nervous system.
Endocrinology, Reproductive/Infertility
Glyburide: Patients receive Glyburide through three trade names including Micronase DiaBeta and Glynase since this second-generation sulfonylurea provides stronger potency while minimizing drug interactions found in first-generation sulfonylureas. Glyburide stands as an alternative treatment option to insulin for managing gestational diabetes even though it lacks specific FDA approval for this medical application.
Glipizide: The second-generation sulfonylurea Glipizide delivers enhanced potency together with reduced drug interactions between this and other first-generation agents. The medication assists natural insulin secretion and produces lesser adverse effects on blood sugar control and body weight than alternative sulfonylurea drugs.
Endocrinology, Reproductive/Infertility
Glucagon: Its function is to elevate blood glucose through blocking glycogen synthesis and supporting gluconeogenesis production primarily from protein and fat-based substances. Through liver hepatic glycogenolysis the breakdown of glycogen into glucose stimulates both lipolysis of adipose tissue and glycogenolysis of liver tissues. Glucagon enhances heart muscle contractions and causes relaxed state of gastrointestinal tract functions.
Endocrinology, Reproductive/Infertility
Repaglinide: It functions well in patients with high hypoglycemia risks whose treatment needs an insulin secretagogue. Pancreatic beta cells release insulin due to this medication while postprandial blood sugar remains in control. The FDA has approved the drug for individual usage as well as pairing it with metformin or thiazolidinediones.
Nateglinide (Starlix): Â It uses mechanisms that duplicate native insulin activity by releasing insulin early in the day while controlling blood glucose spike amounts during meals. Pharmacological studies have established nateglinide as a suitable option for monotherapy treatment of type 2 diabetes or its use with metformin and thiazolidinediones therapies. Both 60 mg and 120 mg Nateglinide are available as tablets in their dosage form.
Endocrinology, Reproductive/Infertility
Miglitol (Glyset): It functions as an unadsorbed FDA-approved pharmaceutical agent that works independently or with sulfonylureas while preserving liver health. These drug characteristics demonstrate both minimal blood sugar reduction together with substantial side effects that cause gas production.
Acarbose (Precose): It provides the first FDA-approved alpha-glucosidase inhibitor treatment because it requires minimal absorption yet it sometimes leads to uncommon liver function problems. Acarbose has two use options as either a single treatment or with other treatment plans.
Endocrinology, Reproductive/Infertility
Pioglitazone (Actos): It is administered to patients alongside dietary modifications and exercise for better type 2 diabetes management through enhanced insulin sensitivity without affecting pancreatic insulin production. Triglyceride levels decrease effectively when patients take this medication due to its PPAR-alpha effect. Professional advice from the FDA states that patients with current bladder cancer must avoid this treatment while healthcare providers need to carefully consider prescribing Actos to those who have battled bladder cancer during the past.
Rosiglitazone (Avandia): It functions as an insulin sensitizer which controls plasma insulin levels by improving glucose uptake in muscle and fat tissues. This medication serves people with type 2 diabetes yet it works best when combined with other therapeutic treatments. The medication helps maintain beta-cell functionality while providing health benefits for blood vessels.
Endocrinology, Reproductive/Infertility
Exenatide Injectable Solution (Byetta): It functions through GLP-1 agonism to help patients with type 2 diabetes control their blood sugar by triggering insulin release in response to glucose while reducing excessive glucagon output and reducing gastric emptying speed. The medicine requires two subcutaneous administrations each day to patients who show inadequate blood sugar management with metformin or sulfonylureas.
Exenatide Injectable Suspension (Bydureon): It enables once-weekly subcutaneous delivery that leads to better glycemic control than Byetta’s twice-daily administration.
Liraglutide (Victoza): It functions as a once-daily GLP-1 receptor agonist that activates pancreatic beta cells to release insulin following blood glucose elevation. Type 2 diabetic adults can take this medication together with diet and exercise yet it functions as secondary treatment only because it carries potentially dangerous adverse effects. The medication must be avoided for patients who have medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 given potential thyroid tumor development concerns.
Endocrinology, Reproductive/Infertility
Sitagliptin (Januvia): It functions as a specific DPP-4 inhibitor which operates without touching either DPP-8 or DPP-9 activity. This drug functions effectively independently or with metformin or thiazolidinediones and patients need to take it once per day. Sitagliptin is weight neutral.
Saxagliptin (Onglyza): It works by blocking DPP-4 activity to enhance the levels of GIP and GLP-1 and subsequently stimulates insulin release for maintaining blood glucose control after meals. The medication functions together with adequate dietary plan and exercise for type 2 diabetes patients aged 18 years and older.
Linagliptin (Tradjenta): It blocks DPP-4 enzyme activity to expand incretin hormone duration thus allowing patients with type 2 diabetes to lower their blood glucose levels. Doctors can prescribe linagliptin either alone or combined with the drugs metformin and sulfonylureas and pioglitazone yet it should not be used with insulin treatment.
Endocrinology, Reproductive/Infertility
Colesevelam (WelChol): It provides glycemic control benefits for type 2 diabetes mellitus patients through its combination with diet and exercise. Experts have not determined all aspects of the method by which this medication improves blood sugar control.
Endocrinology, Reproductive/Infertility
Insulin NPH: It shows three to four hours of onset with peak effects during eight to fourteen hours which result in sixteen to twenty-four hours of duration of action. Patients should mix the insulin carefully because its cloudy appearance and ensures discarding the medicine when clumps develop.
Endocrinology, Reproductive/Infertility
Bromocriptine (Cycloset): It represents the single bromocriptine medicine available for type 2 diabetes mellitus treatment through quick-release formulation. Bromocriptine serves as a supplemental treatment with diet and workout to improve blood sugar control.
Endocrinology, Reproductive/Infertility
The emergency administration of intravenous insulin represents an essential treatment in DKA situations to manage blood glucose levels and stop ketone production.
A subcutaneous insulin therapy such as basal-bolus insulin therapy becomes the starting point for glycemic regulation after patients have stabilized. Normal saline administration through the intravenous route restores both intravascular volume and corrects dehydration problems from DKA.
The assessment of potassium along with other electrolyte levels remains vital due to insulin treatment which causes potassium to reenter cells thereby inducing hypokalemia.
Endocrinology, Reproductive/Infertility
The treatment of ketosis-prone type 2 diabetes requires a step-by-step process which consists of three distinct phases.
The acute phase demands rapid intervention through IV insulin delivery combined with fluid administration to stabilize the patient along with electrolyte control and DKA correction.
During the transition phase patients need to start subcutaneous insulin while receiving education about blood glucose testing and ketone monitoring and learning dietary techniques that stop ketosis from happening.
Regular medical check-ups involve both lifestyle adaptation and the monitoring of glucose levels which helps patients sustain good blood sugar control and avoid further diabetes occurrences.
Ketosis-prone diabetes (KPD) exists as a syndrome which causes diabetic ketoacidosis (DKA) among people who do not show characteristics of typical type 1 or type 2 diabetes diagnosis. The medical community discovered KPD in the 1960s when studying diabetes in African and African American patients which combines characteristics from both diabetes types. The proper management in KPD patients can trigger spontaneous remission that leads to insulin independence together with better insulin sensitivity. Type 1b diabetes and LADA represent the names assigned to KPD which presents DKA symptoms but does not require continuing insulin treatment. According to the Aβ classification system patients receive assessments of their beta-cell reserve combined with their autoantibody status to divide them into four distinct categories. Type 2-like traits require oral medications but patients with permanent insulin dependence need lifelong treatment.
Ketosis-prone diabetes (KPD) affects between 20% to 50% of African American and Hispanic patients who experience diabetic ketoacidosis (DKA) with half of them displaying the A-β+ phenotype in the United States. The frequency of DKA for the population in African countries matches identically with North American populations yet the Asian and White population demographics manifest lower frequencies of DKA at below 10%. The occurrence of KPD appears twice to three times higher in male patients than female patients. The evaluation of KPD normally happens between the ages of thirty and fifty but healthcare providers have spotted this condition in children as well.
The factors that cause diabetic ketoacidosis (DKA) to occur in the A-β+ subgroup of ketosis-prone diabetes (KPD) remain unclear although viral infections, G6PD deficiency-induced oxidative stress and genetics are suspected contributors. Acute hyperglycemia produces substantial impairment of C-peptide response in affected patients according to research findings but chronic hyperglycemia weakens insulin signaling in skeletal muscle resulting in reversible β-cell dysfunction. The detection of B-chain amino acid 9-23-related peptide through immunoreactivity indicates reduced β-cell performance in patients with A-β+ and DKA.
Relevant research continues to investigate the origins of multiple diabetic disorders. The severity of the condition and extent of β-cell destruction align with different epitopes present in glutamic acid decarboxylase antibodies. A-β+ phenotype exists due to three major causes which include viral infections together with genetic factors and oxidative stress. Patients who develop ketosis-prone type 2 diabetes have obesity as well as inherited diabetic conditions in their family history.
The male population bears a higher risk of this condition by a ratio of two to three since hormonal differences combine with body fat distributions and insulin sensitivity levels. The prognosis of ketosis-prone diabetes depends heavily on whether the patient exhibits the Aβ status. People assigned to the β- category maintain their blood sugar control by using insulin treatments which will last for their entire lives. The majority of A-β+ subgroup patients who suffer diabetic ketoacidosis during their first episode subsequently experience treatment-induced sustained remission that leads to insulin-free remission status.
Age Group:
Typically diagnosed in adults, but cases can occur in children.
Altered mental status
Tachycardia
Tachypnea/hyperpnea
Hypotension
Nausea, vomiting
Dry mucous membranes
Poor skin turgor
Signs related to a precipitating illness
“Unprovoked” KPD often lacks precipitating factors, while “provoked” KPD may be linked to acute illnesses (e.g., myocardial infarction, infections).
Patients with long-standing diabetes may show high frequencies of HLA class II susceptibility alleles and T-cell reactivity to islet autoantigens.
Unprovoked KPD: Presents with diabetic ketoacidosis (DKA) without clear triggers. Symptoms include polydipsia, polyuria, and fatigue, with potential for long-term remission and insulin independence.
Provoked KPD: Characterized by a more progressive symptom onset, often associated with acute events. Symptoms may include abdominal pain, which is common, especially in children, and may relate to the severity of acidosis. Shortness of breath despite normal oxygen saturation can also occur.
Type 1 Diabetes Mellitus (T1DM)
Type 2 Diabetes Mellitus (T2DM)
Latent Autoimmune Diabetes in Adults (LADA)
Maturity-Onset Diabetes of the Young (MODY)
Secondary Diabetes
Infections
Acute Management:
The patient requires an intravenous administration of fluids to restore both hydration levels and electrolyte balance.
Insulin Therapy: IV insulin infusion for hyperglycemia and ketosis resolution.
Medical staff will monitor both potassium phosphate and bicarbonate levels along with essential replacements when needed.
Transition to Maintenance:
The vast majority of patients initially need treatment with basal-bolus insulin therapy after being admitted to the hospital.
Some patients require the replacement of original oral hypoglycemic agents with either metformin, SGLT2 inhibitors or GLP-1 receptor agonists.
Long-term Management:
Insulin-dependent individuals have the potential for insulin discontinuation after transferring to management with oral anti-diabetic medications.
The three vital elements for success include modifications to diet and exercise along with managing weight.
Regular Performances of Glucose Testing and Assessment of Ketones Help Identify Relapse.
Endocrinology, Reproductive/Infertility
The dietary management approach includes a balanced diet of whole foods that requires controlled carbohydrate intake to maintain steady blood glucose levels.
Physical activity plays a vital role in maintaining health so recommend at least 150 minutes of aerobic and resistance training performed each week. A healthy weight management plan combining proper nutrition with physical activity helps patients achieve better insulin sensitivity. Reducing blood glucose stress effects through implementation of mindfulness practices with relaxation techniques and sleep hygiene practices. The healthcare provider should deliver diabetes education and teach blood glucose monitoring to patients while training them to detect symptoms of ketosis.
Endocrinology, Reproductive/Infertility
Regular Insulin (Humulin R, Novolin R): Onset in 0.5 hours, peak at 2-4 hours, and duration of 5-8 hours. Available in mixtures with NPH insulin.
Insulin Detemir (Levemir): Long-acting, administered once or twice daily, with a duration of 5.7 to 23.2 hours depending on the dose. It regulates glucose metabolism.
Insulin Glargine (Lantus): Long-acting with a consistent release over 24 hours and no pronounced peaks, but potential cancer risk associated.
Metformin: The diabetes medicine Metformin operates as a solo medication and functions with sulfonylureas and thiazolidinediones and insulin. The patient can minimize gastrointestinal side effects by taking Metformin with food. The drug exists on the market as extended-release forms and also combined with various diabetes treatments. The drug has strict contraindications for patients who have reduced renal function when their serum creatinine reaches levels higher than 1.5 mg/dL in males or 1.4 mg/dL in females or when estimated GFR goes below 60 mL/min. Additionally, metformin should not be used for 48 hours following IV iodinated contrast media treatments.
Endocrinology, Reproductive/Infertility
Pramlintide Acetate: It represents a synthetic version of human amylin hormone which pancreatic beta cells produce and type 1 diabetes patients are lacking. The medication achieves these effects by delaying stomach emptying along with its capability to decrease post-meal glucagon release and through its appetite control mechanisms in the central nervous system.
Endocrinology, Reproductive/Infertility
Glyburide: Patients receive Glyburide through three trade names including Micronase DiaBeta and Glynase since this second-generation sulfonylurea provides stronger potency while minimizing drug interactions found in first-generation sulfonylureas. Glyburide stands as an alternative treatment option to insulin for managing gestational diabetes even though it lacks specific FDA approval for this medical application.
Glipizide: The second-generation sulfonylurea Glipizide delivers enhanced potency together with reduced drug interactions between this and other first-generation agents. The medication assists natural insulin secretion and produces lesser adverse effects on blood sugar control and body weight than alternative sulfonylurea drugs.
Endocrinology, Reproductive/Infertility
Glucagon: Its function is to elevate blood glucose through blocking glycogen synthesis and supporting gluconeogenesis production primarily from protein and fat-based substances. Through liver hepatic glycogenolysis the breakdown of glycogen into glucose stimulates both lipolysis of adipose tissue and glycogenolysis of liver tissues. Glucagon enhances heart muscle contractions and causes relaxed state of gastrointestinal tract functions.
Endocrinology, Reproductive/Infertility
Repaglinide: It functions well in patients with high hypoglycemia risks whose treatment needs an insulin secretagogue. Pancreatic beta cells release insulin due to this medication while postprandial blood sugar remains in control. The FDA has approved the drug for individual usage as well as pairing it with metformin or thiazolidinediones.
Nateglinide (Starlix): Â It uses mechanisms that duplicate native insulin activity by releasing insulin early in the day while controlling blood glucose spike amounts during meals. Pharmacological studies have established nateglinide as a suitable option for monotherapy treatment of type 2 diabetes or its use with metformin and thiazolidinediones therapies. Both 60 mg and 120 mg Nateglinide are available as tablets in their dosage form.
Endocrinology, Reproductive/Infertility
Miglitol (Glyset): It functions as an unadsorbed FDA-approved pharmaceutical agent that works independently or with sulfonylureas while preserving liver health. These drug characteristics demonstrate both minimal blood sugar reduction together with substantial side effects that cause gas production.
Acarbose (Precose): It provides the first FDA-approved alpha-glucosidase inhibitor treatment because it requires minimal absorption yet it sometimes leads to uncommon liver function problems. Acarbose has two use options as either a single treatment or with other treatment plans.
Endocrinology, Reproductive/Infertility
Pioglitazone (Actos): It is administered to patients alongside dietary modifications and exercise for better type 2 diabetes management through enhanced insulin sensitivity without affecting pancreatic insulin production. Triglyceride levels decrease effectively when patients take this medication due to its PPAR-alpha effect. Professional advice from the FDA states that patients with current bladder cancer must avoid this treatment while healthcare providers need to carefully consider prescribing Actos to those who have battled bladder cancer during the past.
Rosiglitazone (Avandia): It functions as an insulin sensitizer which controls plasma insulin levels by improving glucose uptake in muscle and fat tissues. This medication serves people with type 2 diabetes yet it works best when combined with other therapeutic treatments. The medication helps maintain beta-cell functionality while providing health benefits for blood vessels.
Endocrinology, Reproductive/Infertility
Exenatide Injectable Solution (Byetta): It functions through GLP-1 agonism to help patients with type 2 diabetes control their blood sugar by triggering insulin release in response to glucose while reducing excessive glucagon output and reducing gastric emptying speed. The medicine requires two subcutaneous administrations each day to patients who show inadequate blood sugar management with metformin or sulfonylureas.
Exenatide Injectable Suspension (Bydureon): It enables once-weekly subcutaneous delivery that leads to better glycemic control than Byetta’s twice-daily administration.
Liraglutide (Victoza): It functions as a once-daily GLP-1 receptor agonist that activates pancreatic beta cells to release insulin following blood glucose elevation. Type 2 diabetic adults can take this medication together with diet and exercise yet it functions as secondary treatment only because it carries potentially dangerous adverse effects. The medication must be avoided for patients who have medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 given potential thyroid tumor development concerns.
Endocrinology, Reproductive/Infertility
Sitagliptin (Januvia): It functions as a specific DPP-4 inhibitor which operates without touching either DPP-8 or DPP-9 activity. This drug functions effectively independently or with metformin or thiazolidinediones and patients need to take it once per day. Sitagliptin is weight neutral.
Saxagliptin (Onglyza): It works by blocking DPP-4 activity to enhance the levels of GIP and GLP-1 and subsequently stimulates insulin release for maintaining blood glucose control after meals. The medication functions together with adequate dietary plan and exercise for type 2 diabetes patients aged 18 years and older.
Linagliptin (Tradjenta): It blocks DPP-4 enzyme activity to expand incretin hormone duration thus allowing patients with type 2 diabetes to lower their blood glucose levels. Doctors can prescribe linagliptin either alone or combined with the drugs metformin and sulfonylureas and pioglitazone yet it should not be used with insulin treatment.
Endocrinology, Reproductive/Infertility
Colesevelam (WelChol): It provides glycemic control benefits for type 2 diabetes mellitus patients through its combination with diet and exercise. Experts have not determined all aspects of the method by which this medication improves blood sugar control.
Endocrinology, Reproductive/Infertility
Insulin NPH: It shows three to four hours of onset with peak effects during eight to fourteen hours which result in sixteen to twenty-four hours of duration of action. Patients should mix the insulin carefully because its cloudy appearance and ensures discarding the medicine when clumps develop.
Endocrinology, Reproductive/Infertility
Bromocriptine (Cycloset): It represents the single bromocriptine medicine available for type 2 diabetes mellitus treatment through quick-release formulation. Bromocriptine serves as a supplemental treatment with diet and workout to improve blood sugar control.
Endocrinology, Reproductive/Infertility
The emergency administration of intravenous insulin represents an essential treatment in DKA situations to manage blood glucose levels and stop ketone production.
A subcutaneous insulin therapy such as basal-bolus insulin therapy becomes the starting point for glycemic regulation after patients have stabilized. Normal saline administration through the intravenous route restores both intravascular volume and corrects dehydration problems from DKA.
The assessment of potassium along with other electrolyte levels remains vital due to insulin treatment which causes potassium to reenter cells thereby inducing hypokalemia.
Endocrinology, Reproductive/Infertility
The treatment of ketosis-prone type 2 diabetes requires a step-by-step process which consists of three distinct phases.
The acute phase demands rapid intervention through IV insulin delivery combined with fluid administration to stabilize the patient along with electrolyte control and DKA correction.
During the transition phase patients need to start subcutaneous insulin while receiving education about blood glucose testing and ketone monitoring and learning dietary techniques that stop ketosis from happening.
Regular medical check-ups involve both lifestyle adaptation and the monitoring of glucose levels which helps patients sustain good blood sugar control and avoid further diabetes occurrences.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
